Renaissance Technologies LLC Has $509.35 Million Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Renaissance Technologies LLC lowered its position in Exelixis, Inc. (NASDAQ:EXEL) by 0.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 15,295,865 shares of the biotechnology company’s stock after selling 64,051 shares during the quarter. Exelixis comprises approximately 0.8% of Renaissance Technologies LLC’s investment portfolio, making the stock its 9th biggest holding. Renaissance Technologies LLC owned 0.05% of Exelixis worth $509,352,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in EXEL. Rathbones Group PLC acquired a new stake in shares of Exelixis in the 4th quarter worth approximately $216,000. Invesco Ltd. raised its holdings in shares of Exelixis by 308.1% in the 4th quarter. Invesco Ltd. now owns 3,975,241 shares of the biotechnology company’s stock worth $132,376,000 after purchasing an additional 3,001,204 shares in the last quarter. Cerity Partners LLC lifted its stake in Exelixis by 163.9% during the fourth quarter. Cerity Partners LLC now owns 73,884 shares of the biotechnology company’s stock valued at $2,413,000 after purchasing an additional 45,890 shares during the last quarter. FMR LLC boosted its holdings in Exelixis by 19.7% during the fourth quarter. FMR LLC now owns 2,947,599 shares of the biotechnology company’s stock worth $98,155,000 after buying an additional 485,527 shares in the last quarter. Finally, Federated Hermes Inc. increased its holdings in shares of Exelixis by 82.9% in the fourth quarter. Federated Hermes Inc. now owns 408,932 shares of the biotechnology company’s stock valued at $13,637,000 after buying an additional 185,389 shares in the last quarter. Institutional investors own 85.27% of the company’s stock.

Insider Activity at Exelixis

In other Exelixis news, EVP Patrick J. Haley sold 52,636 shares of the company’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $36.98, for a total transaction of $1,946,479.28. Following the completion of the sale, the executive vice president now owns 303,310 shares in the company, valued at approximately $11,216,403.80. The trade was a 14.79 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Bob Oliver sold 18,647 shares of the business’s stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $37.25, for a total value of $694,600.75. Following the transaction, the director now owns 33,514 shares of the company’s stock, valued at $1,248,396.50. The trade was a 35.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 140,343 shares of company stock valued at $5,177,234 over the last quarter. Corporate insiders own 2.85% of the company’s stock.

Exelixis Trading Up 0.8 %

NASDAQ EXEL opened at $34.84 on Tuesday. The company has a 50 day moving average of $35.94 and a 200-day moving average of $33.70. Exelixis, Inc. has a 1-year low of $20.14 and a 1-year high of $40.02. The firm has a market cap of $9.75 billion, a price-to-earnings ratio of 19.68, a PEG ratio of 1.13 and a beta of 0.57.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. On average, analysts forecast that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Barclays increased their price target on Exelixis from $25.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, February 13th. Bank of America lowered shares of Exelixis from a “buy” rating to a “neutral” rating and upped their price objective for the company from $35.00 to $39.00 in a research note on Tuesday, December 17th. Wells Fargo & Company cut shares of Exelixis from an “overweight” rating to an “equal weight” rating and set a $36.00 price target on the stock. in a report on Monday, February 24th. Oppenheimer cut Exelixis from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $41.00 to $33.00 in a research report on Friday, January 24th. Finally, Truist Financial raised their price target on Exelixis from $42.00 to $43.00 and gave the stock a “buy” rating in a research note on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $37.59.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.